Bristol Myers details PhIII win in first-line test of Reblozyl for reducing transfusions in early blood cancer patients
Reblozyl, a drug that spurs bone marrow to make more blood cells, helped nearly twice as many anemic patients with an early form of blood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
